Non-Hodgkin Lymphoma | Specialty

Fate Therapeutics Receives FDA Clearance of IND for FT819 in B-Cell Malignancies

July 22nd 2020

The FDA has cleared an investigational new drug application for the first-of-its-kind, off-the-shelf CAR T-cell product FT819, which targets CD19-positive malignancies.

Dr. Leslie on the Encouraging Evolving Treatment Landscape in MCL

July 21st 2020

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies

July 20th 2020

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

Ongoing Trial Evaluates Zanubrutinib in BTK-Intolerant B-Cell Malignancies

July 17th 2020

Ian W. Flinn, MD, PhD, discusses the adverse effects associated with BTK inhibitors in B-cell malignancies, as well as the design of an ongoing phase 2 study with zanubrutinib.

Novel Therapies: R2-GDP-GOTEL and Smart Start

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

July 17th 2020

Relapsed/Refractory DLBCL: Unmet Needs

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

July 17th 2020

SADAL Trial Regimen FDA Approval

July 17th 2020

SADAL Trial Overview

July 17th 2020

CAR T-Cell Therapy Clinical Trials

July 17th 2020

CAR T-Cell Therapy Response Rates

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

July 17th 2020

DLBCL Risk Assessment and Genetic Signatures

July 17th 2020

Therapy Initiation Prior to Cytogenetic Testing Results

July 17th 2020

Closing Thoughts on Treatment of R/R DLBCL

July 15th 2020

Improving Outcomes in Patients With R/R DLBCL

July 15th 2020